HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism.

AbstractRATIONALE:
The neuropeptide secretoneurin induces angiogenesis and postnatal vasculogenesis and is upregulated by hypoxia in skeletal muscle cells.
OBJECTIVE:
We sought to investigate the effects of secretoneurin on therapeutic angiogenesis.
METHODS AND RESULTS:
We generated a secretoneurin gene therapy vector. In the mouse hindlimb ischemia model secretoneurin gene therapy by intramuscular plasmid injection significantly increased secretoneurin content of injected muscles, improved functional parameters, reduced tissue necrosis, and restored blood perfusion. Increased muscular density of capillaries and arterioles/arteries demonstrates the capability of secretoneurin gene therapy to induce therapeutic angiogenesis and arteriogenesis. Furthermore, recruitment of endothelial progenitor cells was enhanced by secretoneurin gene therapy consistent with induction of postnatal vasculogenesis. Additionally, secretoneurin was able to activate nitric oxide synthase in endothelial cells and inhibition of nitric oxide inhibited secretoneurin-induced effects on chemotaxis and capillary tube formation in vitro. In vivo, secretoneurin induced nitric oxide production and inhibition of nitric oxide attenuated secretoneurin-induced effects on blood perfusion, angiogenesis, arteriogenesis, and vasculogenesis. Secretoneurin also induced upregulation of basic fibroblast growth factor and platelet-derived growth factor-B in endothelial cells.
CONCLUSIONS:
In summary, our data indicate that gene therapy with secretoneurin induces therapeutic angiogenesis, arteriogenesis, and vasculogenesis in the hindlimb ischemia model by a nitric oxide-dependent mechanism.
AuthorsWilfried Schgoer, Markus Theurl, Johannes Jeschke, Arno G E Beer, Karin Albrecht, Roland Gander, Song Rong, Danijela Vasiljevic, Margot Egger, Anna Maria Wolf, Silke Frauscher, Bernhard Koller, Ivan Tancevski, Josef R Patsch, Peter Schratzberger, Hildegunde Piza-Katzer, Andreas Ritsch, Ferdinand H Bahlmann, Reiner Fischer-Colbrie, Dominik Wolf, Rudolf Kirchmair
JournalCirculation research (Circ Res) Vol. 105 Issue 10 Pg. 994-1002 (Nov 06 2009) ISSN: 1524-4571 [Electronic] United States
PMID19797703 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inducing Agents
  • Cytokines
  • Neuropeptides
  • Secretogranin II
  • secretoneurin
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
Topics
  • Angiogenesis Inducing Agents (metabolism)
  • Animals
  • Cytokines (biosynthesis, genetics)
  • Disease Models, Animal
  • Endothelial Cells (metabolism)
  • Genetic Therapy
  • Hindlimb (blood supply, metabolism)
  • Humans
  • Ischemia (genetics, metabolism, therapy)
  • Mice
  • Neovascularization, Physiologic
  • Neuropeptides (biosynthesis, genetics)
  • Nitric Oxide (metabolism)
  • Nitric Oxide Synthase Type III (biosynthesis)
  • Secretogranin II (biosynthesis, genetics)
  • Stem Cells (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: